RANI Share Price Performance
US$0.73
-0.66 (-47.14%)
93.3% undervalued intrinsic discount
US$11.00
Fair Value
Price US$0.73
AnalystHighTarget US$11.00
AnalystConsensusTarget US$9.25
AnalystLowTarget US$5.00
Fair ValueUS$11.00
Share Pricen/a
Rani Therapeutics Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 25 Fair Values set on narratives written by author
RANI Community Narratives
AN
Fair Value US$11 92.7% undervalued intrinsic discount
Needle-Free Oral Biologics Will Serve Aging Global Demand
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$9.25 91.3% undervalued intrinsic discount
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value US$5 83.9% undervalued intrinsic discount
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Catalysts About Rani Therapeutics Holdings Rani Therapeutics Holdings is a clinical stage biotherapeutics company focused on enabling oral delivery of biologic drugs through its RaniPill capsule platform. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$5
83.9% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
181.36x
Price in 2029
US$6.12
Needle-Free Oral Biologics Will Serve Aging Global Demand
Key Takeaways Rani's oral therapy platform offers a significant adoption advantage and margin potential due to its non-invasive delivery and superior performance versus injections. Advancements in manufacturing and partnerships position the company for strong long-term growth while reducing reliance on dilutive financing.Read more
105
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$11
92.7% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
250.88x
Price in 2029
US$13.45
RANI: Future Pharma Partnership Will Unlock Major Deal Value Uplift
Key Takeaways RaniPill technology and RT-114 partnership position Rani Therapeutics to capture significant market share and boost future revenue. Extensive patent portfolio and cost containment measures enhance protection, licensing opportunities, and improve net margins.Read more
406
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
US$9.25
91.3% undervalued intrinsic discount
Fair Value
Profit Margin
20.87%
Future PE
227.34x
Price in 2028
US$11.27
Trending Discussion
Recently Updated Narratives
AN
Early Clinical Uncertainty And Cash Runway Risk Will Shape Platform Potential Later
Fair Value: US$5 83.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RANI: Obesity Capsule Trial Progress Will Drive Stronger Future Upside Potential
Fair Value: US$11 92.7% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RANI: Collaboration With Chugai And Cash Infusion Will Drive Future Upside
Fair Value: US$9.25 91.3% undervalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Rani Therapeutics Holdings, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.30
- 100.00%
- -1,817.09%
- 0%
About RANI
- Founded
- 2012
- Employees
- 106
- CEO
- WebsiteView website
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
